Merz Americas Rhatigan Chosen as PharmaVOICE 100 Award Recipient

Merz CEO Honored

Bob Rhatigan, CEO of Merz Americas, has been named one of the top 100 most inspiring and influential life sciences leaders by PharmaVOICE magazine, a healthcare trade publication. The annual PharmaVOICE 100 awards recognize inspirational, motivational and transformative individuals in life sciences who positively impact their colleagues, peers, organizations and the industry.

Merz Creates Americas Region and Expands Rhatigan’s Role

Merz Launches Americas Division

Bob Rhatigan, CEO of Merz North America, has been appointed to a new position in the company, president and CEO of Merz-Americas effective September 1. This expands Rhatigan’s leadership of Merz’s North American business as he assumes responsibility for Latin America and will oversee the overall commercial strategy for the company’s newly created “Americas Region.” In addition, Frank Brandt-Pollmann has been promoted to area vice president, Latin America. He will lead Merz’s business operations across Latin America and report directly to Rhatigan.

Merz North America Appoints New CFO

Merz announces new CFO

Alana Sine is the new chief financial officer of Merz North America. Sine has served as interim CFO since March 2018. Over the course of her 13-year tenure at Merz, Sine assumed finance roles of increasing responsibility. As interim CFO, she successfully led the budget and strategic planning process for the coming fiscal year. Prior to joining Merz, Sine held accounting and finance roles at Ernst & Young (now EY) and Lowe’s Food Stores.

Evaluating CaHA Injection Complications

Evaluating CaHa Injection Complications

In an effort to compile more objective data regarding calcium hydroxylapatite (CaHA, Radiesse) injections, researchers Xiao-hua Shi, PhD, et al, examined previous studies to evaluate the complications from CaHA injection for facial soft tissue augmentation. They identified published studies on CaHA injection for facial soft tissue enhancement via PubMed, EMBASE and Cochrane Controlled Trial databases. Only randomized, controlled trials comparing CaHA injection to either placebo or an active comparator for facial cosmetic use were included.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

Cellfina System Approved by FDA

Cellfina System Approved by FDA

The U.S. Food and Drug Administration (FDA) has cleared the Cellfina System (Ulthera) for long-term improvement (up to two years) in the appearance of cellulite on the buttocks and thighs. The Cellfina System combines highly advanced, proprietary technology with subcision to treat the primary structural cause of cellulite.

Merz To Acquire Ulthera


Merz and Ulthera have entered into a definitive merger agreement, pursuant to which Merz will acquire global medical device company Ulthera, which developed the ultrasound-based Ultherapy technology for noninvasive skin tightening and lifting. Valued at up to $600 million in upfront cash and milestone payments, the acquisition is the largest in Merz’s history.

Merz Signs Licensing Agreement For Development Of A Novel Retinoid Therapy

Merz North America has signed an agreement with Brickell Biotech, granting Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a novel retinoid compound for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under the terms of the agreement, Merz North America will assume the full cost and responsibility for future development and commercialization, initially for North America.

Merz Provides Educational Grant for Derm In-Review

Merz North America has stepped in with an educational grant to ensure that the national Derm In-Review training program will remain available to residents preparing for their Board certifying exams.

“As a company committed to the future of dermatology and educational opportunities for members of the specialty, Merz is proud to offer this educational grant to Derm In-Review,” said Jim Hartman, vice president, Aesthetics and OTC for Merz North America. “We look forward to a continued partnership with this iconic program.”